Juno, Editas Form Cell Therapy Pact | Chemical & Engineering News
Volume 93 Issue 22 | p. 17 | Concentrates
Issue Date: June 1, 2015

Juno, Editas Form Cell Therapy Pact

Department: Business
Keywords: biotech, gene editing, CRISPR, CART, cell therapy

In a pact that combines two hot technologies, the T-cell-based therapies developer Juno Therapeutics will pay $25 million to Editas Medicine to use its CRISPR/Cas9 gene-editing capabilities. Editas also will get $22 million in R&D support over the next five years. Juno genetically engineers a cancer patient’s T cells to detect and kill diseased cells. Gene-editing technology from Editas could help broaden the effectiveness of the engineered T cells beyond certain blood cancers to solid tumors.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment